Production & Sales

Tris Pharma recalls infants’ liquid Ibuprofen in US

Tris Pharma has voluntarily recalled three lots of Infants' Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level in the US.

Crown Laboratories buys select OTC consumer healthcare brands from GSK

Crown Laboratories, a privately held, fully integrated global skin care company, has acquired North American distribution rights of five OTC consumer brands from GlaxoSmithKline (GSK).

GSK, Kyowa Hakko Kirin to commercialize anemia drug daprodustat in Japan

British drugmaker GlaxoSmithKline (GSK) has entered into a collaboration with Kyowa Hakko Kirin to commercialize daprodustat in Japan.

Cambrex to acquire contract drug developer Avista Pharma for $252m

Life sciences company Cambrex has agreed to acquire Avista Pharma Solutions, a North Carolina-based contract development, manufacturing, and testing organization, for about $252m.

Nexus Pharmaceuticals gets FDA nod for Arsenic Trioxide injection in 10mg per 10mL vial

Nexus Pharmaceuticals has announced the immediate availability of Arsenic Trioxide Injection in 10mg per 10mL vial in the US.

AstraZeneca to sell Synagis US rights to Sobi for $1.5bn

AstraZeneca has agreed to offload the US rights of its respiratory drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) in a cash-cum-stock deal worth $1.5bn.

Ferring launches Nocdurna in US to treat nocturia due to NP

Ferring Pharmaceuticals has announced the US launch of NOCDURNA (desmopressin acetate), a sublingual tablet indicated for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken more than two times per night to void.

AstraZeneca to sell asthma and rhinitis drug rights to Covis Pharma for $350m

AstraZeneca has agreed to offload its rights to asthma drug Alvesco (ciclesonide) and nasal sprays Omnaris and Zetonna (ciclesonide) to Covis Pharma for $350m.

Quotient Sciences extends formulation and manufacturing operations in UK

Quotient Sciences, a global pharmaceutical development, clinical pharmacology and clinical and commercial manufacturing organization, has significantly expanded its formulation development and clinical trial manufacturing operations at its Reading facility, UK.